Kailera Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is KLRA moving today?
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for KLRA.
KLRA insider activity
Kailera Therapeutics, Inc. Common Stock
2 insiders bought in the last 90 days
Net buying: $8.2M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-11 | 2026-06-09 | Renaud Ronald C JR | Insider | buy | $5.25 | 38,094 | 38,094 | $200K | SEC Form 4 |
| 2026-04-22 | 2026-04-20 | RTW INVESTMENTS, LP | Insider | buy | $16.00 | 500,000 | 10,776,820 | $8.0M | SEC Form 4 |
KLRA contract awards, year to date.
Public federal awards linked to this ticker.
KLRA lobbying filings, year to date.
Registered lobbying filings matched to Kailera Therapeutics, Inc. Common Stock.